Krystal Biotech Q3 product revenue rises 30% on VYJUVEK demand
KRYS•Krystal Biotech’s third-quarter product revenue rose 30% year over year to $127.34 million, while net income fell to $63.07 million. The company authorized a $400 million share repurchase program and expects to launch VYJUVEK in Italy in early 2027.
1. Revenue and net income
Krystal Biotech reported third-quarter product revenue of $127.34 million, up 30% year over year, driven by VYJUVEK sales growth. Net income declined year over year to $63.07 million, reflecting increased costs and tax expense.
2. Outlook and buyback
The company authorized a $400 million share repurchase program. It expects to launch VYJUVEK in Italy in early 2027 and forecasts fiscal 2026 non-GAAP research and development and selling, general and administrative expenses of $155 million to $165 million. Krystal expects interim results from its KB111 study before year end.
3. VYJUVEK demand
Krystal said U.S. patient demand continues to grow, with more than 760 reimbursement approvals and an expanding prescriber base. Expansion in Germany, France and Japan is broadening the prescriber base, and the company completed pricing negotiations in Germany and Italy.
